New Article in ACT

ACTIn Applied Clinical Trials journal appeared an article, which investigates the question of site screening due diligence and how it can improve patient dropout rates – “RbM Data Reveals Site Screening Due Diligence Improves Patient Dropout and Retention”. The investigations for the article were done applying the Cyntegrity’s RbM System EarlyBird®.

Read more here:

http://www.appliedclinicaltrialsonline.com/rbm-data-reveals-site-screening-due-diligence-improves-patient-dropout-and-retention

Cyntegrity is happy to support researchers in this field with technology and information.

Are you a young researcher in the area clinical risk management and RbM and would like to get Cyntegrity’s support for your research project?

Contact Us

By | 2016-11-16T18:35:47+00:00 March 19, 2015|News|0 Comments

About the Author:

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.

Leave A Comment

Upcoming Events

  1. SCDM 2018 ANNUAL CONFERENCE – Seattle

    September 23 - September 26
  2. PCT Europe 2018

    November 28 - November 29

Register Today!

Get Free Test Access